Delisting, debt, and a vapor pivot: What’s next for struggling cannabis firm TILT Holdings?

Why is TILT Holdings being delisted and what does this mean for shareholders?

TILT Holdings Inc., listed on Cboe Canada under the ticker symbol TILT and on the OTCID in the United States as TLLTF, is set to be delisted from Cboe Canada effective November 18, 2025. This follows a suspension in trading of its securities initiated on November 7. The development comes as the cannabis hardware and support services company moves into formal restructuring under the Companies’ Creditors Arrangement Act, or CCAA, in British Columbia.

According to the company’s disclosure, the delisting was triggered under Section 11.03 of the Cboe Canada listing manual. The company received an official notice from Cboe Canada, which confirmed that its common shares would be removed from the exchange. Notably, the exchange stated there would be no guarantee that trading would resume before the delisting becomes effective. On the same day, TILT Holdings Inc.’s shares were also halted from quotation on the OTCID, operated by OTC Markets Group in the United States. This dual trading freeze severely limits liquidity and investor access to the stock, particularly affecting retail shareholders who may not have visibility into over-the-counter platforms or the company’s restructuring pathway.

The decision to delist and suspend trading appears closely tied to TILT Holdings Inc.’s financial restructuring plans and the strategic transformation of its business model. Market observers note that delisting in the midst of a court-supervised restructuring often results in loss of shareholder value and makes it difficult for existing investors to exit or adjust their holdings.

What triggered the court protection and what are the key elements of the restructuring?

On November 7, 2025, TILT Holdings Inc. received initial court protection under the Companies’ Creditors Arrangement Act from the Supreme Court of British Columbia. The company stated that the move was part of a larger plan to restructure its operations and debt obligations. This includes a Restructuring Support Agreement entered into with a group of senior secured noteholders. The agreement outlines a strategy to reduce the company’s liabilities, recapitalize certain portions of the balance sheet, and streamline its corporate structure.

As part of the restructuring process, TILT Holdings Inc. intends to transition away from its previous plant-touching operations in cannabis cultivation and retail, and instead focus entirely on its subsidiary Jupiter Research LLC. Jupiter Research is a U.S.-based vaporization hardware manufacturer that serves cannabis brands and retailers globally. The hardware firm recently announced that it had received EU medical device certification for its liquid-based inhalation device, a development that may allow it to access regulated European markets more effectively.

In addition to its shift in operating model, TILT Holdings Inc. is seeking to refinance its existing senior notes, secure new credit facilities to replace its current arrangements, and implement significant reductions in overhead costs. This includes workforce reduction and a narrower operating footprint. The strategy is designed to conserve cash, enhance operational efficiency, and focus resources on its most competitive and scalable business line.

How have financial and operational challenges led to this point?

The need for a court-supervised restructuring process became increasingly likely following a series of quarterly losses, revenue declines, and operational divestitures. In the second quarter of 2025, TILT Holdings Inc. reported total revenue from continuing operations of approximately USD 10.5 million. This marked a significant drop from USD 19 million in the same quarter of the previous year. The company’s gross margin for the quarter was 17.4 percent, signaling severe pressure on profitability and challenges in maintaining economies of scale after downsizing its asset base.

This contraction in top-line performance followed the company’s previously announced sale of its Massachusetts-based dispensary network and the wind-down of other state-level plant-touching assets. These included vertical integration models that required high levels of capital expenditure, compliance costs, and regulatory overhead. The company’s management has repeatedly stated that such assets were no longer core to its long-term strategic vision.

Industry analysts covering the cannabis and wellness sectors point out that vertically integrated operators in the United States have increasingly faced compression in wholesale prices, challenges accessing working capital, and regulatory fragmentation across different states. TILT Holdings Inc. had previously attempted to differentiate itself through a multi-state operating footprint, but as market conditions shifted, it became evident that such a strategy lacked the resilience needed to sustain performance without continuous capital infusion.

What are the risks for shareholders as the company transitions out of public markets?

The transition away from public markets introduces considerable uncertainty for current shareholders of TILT Holdings Inc. Once the company is delisted from Cboe Canada, and while its shares remain halted on the OTCID, retail investors will have limited or no access to secondary trading platforms. This severely impacts liquidity and increases the probability of capital impairment for existing shareholders.

Historically, companies undergoing creditor-led restructurings under CCAA or similar legal frameworks often eliminate or heavily dilute common equity in favor of senior claims and new financing. The company has not made any guarantees about the future of its common shares, and no recovery plan for retail equity holders has been disclosed as of this writing. Given the capital structure and the significant reduction in operating income, market participants suggest that common shareholders face an uphill battle in retaining any meaningful residual value once the restructuring is complete.

Another concern involves the lack of public reporting post-delisting. With fewer regulatory requirements and reduced disclosure, it becomes increasingly difficult for investors and analysts to track the company’s performance, governance, or future financing actions. While the company has indicated it will continue to operate Jupiter Research and pursue strategic growth through that subsidiary, the lack of transparency could weigh on investor confidence even if the turnaround is successful.

What future outcomes are being considered for the Jupiter Research-led business?

Despite the operational setbacks and financial distress, TILT Holdings Inc. remains committed to building a future around Jupiter Research LLC. The subsidiary is positioned as a core technology and manufacturing platform in the vaporization hardware segment. It serves cannabis companies across North America, South America, Israel, and the European Union. The recent EU medical device certification was highlighted by the company as a gateway to broader market access for its new inhalation product.

According to statements made by the company’s leadership, the certification allows the product to be marketed in several European countries under regulated medical frameworks, a development that may open new revenue channels outside the highly saturated North American market. The company also emphasized its plans to raise debtor-in-possession financing to support ongoing operations, while actively seeking to replace its existing debt facilities with more flexible and supportive arrangements.

Still, sector analysts remain cautious. They note that while Jupiter Research may offer potential upside due to its intellectual property and regulatory clearances, actual commercialization timelines, distribution agreements, and market penetration metrics have yet to be disclosed. Until more is known about unit economics, manufacturing capacity, and global sales performance, the future value of the business remains speculative.

What are the broader sector implications and how are peer firms responding?

The delisting and restructuring of TILT Holdings Inc. add to a growing list of challenges facing mid-sized cannabis operators in North America. With oversupply, pricing erosion, and rising compliance burdens, many companies are being forced to abandon vertically integrated models in favor of capital-light strategies. This includes licensing, contract manufacturing, and ancillary services such as hardware, logistics, and branding.

TILT Holdings Inc.’s decision to pivot entirely to vaporization hardware could signal a longer-term realignment within the cannabis value chain, where equipment manufacturers and service providers assume greater strategic importance. Other firms operating in the cannabis technology and hardware segment may also benefit from reduced competition if TILT’s restructuring results in operational streamlining rather than dissolution.

For the industry at large, the episode underscores the volatility still inherent in cannabis investing. Despite broader policy shifts and increased social acceptance, structural barriers remain in place. For companies unable to differentiate through technology, efficiency, or regulatory expertise, the path forward will likely involve distressed asset sales, mergers, or controlled exits from public markets.

What are the key takeaways from TILT Holdings Inc.’s delisting and restructuring announcement?

• TILT Holdings Inc. will be delisted from Cboe Canada on November 18, 2025, after trading was suspended on November 7 under Section 11.03 of the exchange’s rules.

• The cannabis hardware and services company has entered court-supervised restructuring under the Companies’ Creditors Arrangement Act in British Columbia.

• The restructuring process includes a support agreement with senior secured noteholders, with plans to reduce debt and exit plant-touching operations.

• TILT Holdings Inc. will pivot its focus exclusively to Jupiter Research LLC, its vaporization hardware subsidiary, which recently received EU medical device certification.

• Second-quarter 2025 financial results showed a revenue decline to USD 10.5 million with a gross margin of 17.4 percent, highlighting ongoing financial pressure.

• Common equity holders face liquidity risks and potential capital loss, with trading also halted on OTCID and no guarantee of future relisting.

• The company aims to secure new financing and streamline its operating model, but analysts remain cautious about recovery prospects.

• The delisting reflects broader structural challenges in the cannabis sector, with many firms shifting to capital-light, ancillary-service models for sustainability.